1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. INKON Life Technology Co., Ltd.
  6. News
  7. Summary
    300143   CNE100000XF6

INKON LIFE TECHNOLOGY CO., LTD.

(300143)
  Report
End-of-day quote Shenzhen Stock Exchange  -  05-17
8.470 CNY   -0.70%
04/28INKON Life Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
04/22INKON Life Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
01/11Tranche Update on INKON Life Technology Co., Ltd.'s Equity Buyback Plan announced on February 5, 2021.
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Qingdao Yingkang Medical Investment Co., Ltd. acquired Hangzhou Yikang Traditional Chinese Medicine Tumor Hospital Co., Ltd. from INKON Life Technology Co., Ltd. for CNY 1.3 million.

09/13/2021 EDT

Qingdao Yingkang Medical Investment Co., Ltd. agreed to acquire Hangzhou Yikang Traditional Chinese Medicine Tumor Hospital Co., Ltd. from INKON Life Technology Co., Ltd. (SZSE:300143) for CNY 1.3 million on August 6, 2021. The price of this equity transfer was based on the evaluation results and negotiated by both parties to the transaction. The price of the creditor’s rights transfer is the sum of the principal of the loan under the "Loan Contract" that the company has on Hangzhou Yikang (the upper limit of the loan is CNY 82 million. The specific amount is based on the actual loan amount as of the date of payment of the consideration for this transaction) and the corresponding amount of all the corresponding interest incurred according to the "Loan Contract" (calculated until the payment date of the creditor’s rights transfer consideration). As of August 30, 2021, INKON Life Technology Co., Ltd. shareholders approved the transaction in special shareholders’ meeting. Qingdao Yingkang Medical Investment Co., Ltd. completed the acquisition of Hangzhou Yikang Traditional Chinese Medicine Tumor Hospital Co., Ltd. from INKON Life Technology Co., Ltd. (SZSE:300143) on September 10, 2021.


© S&P Capital IQ 2021
All news about INKON LIFE TECHNOLOGY CO., LTD.
04/28INKON Life Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended Ma..
CI
04/22INKON Life Technology Co., Ltd. Reports Earnings Results for the Full Year Ended Decemb..
CI
01/11Tranche Update on INKON Life Technology Co., Ltd.'s Equity Buyback Plan announced on Fe..
CI
01/11INKON Life Technology Co., Ltd.'s Equity Buyback announced on February 5, 2021, has exp..
CI
01/04Tranche Update on INKON Life Technology Co., Ltd.'s Equity Buyback Plan announced on Fe..
CI
2021INKON Life Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended Sept..
CI
2021Tranche Update on INKON Life Technology Co., Ltd.'s Equity Buyback Plan announced on Fe..
CI
2021INKON LIFE TECHNOLOGY CO., LTD.(XSEC : 300143) added to S&P Global BMI Index
CI
2021Qingdao Yingkang Medical Investment Co., Ltd. acquired Hangzhou Yikang Traditional Chin..
CI
2021China cracks down on showbiz for 'polluting' society and youth
RE
More news
Financials
Sales 2022 1 467 M 218 M 218 M
Net income 2022 206 M 30,5 M 30,5 M
Net Debt 2022 - - -
P/E ratio 2022 26,7x
Yield 2022 -
Capitalization 5 418 M 804 M 804 M
Capi. / Sales 2022 3,69x
Capi. / Sales 2023 3,02x
Nbr of Employees 1 791
Free-Float 21,3%
Chart INKON LIFE TECHNOLOGY CO., LTD.
Duration : Period :
INKON Life Technology Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INKON LIFE TECHNOLOGY CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 8,53 CNY
Average target price 10,81 CNY
Spread / Average Target 26,7%
EPS Revisions
Managers and Directors
Zhi Li Huang Chief Financial Officer
Li Xia Tan Chairman
Long Ping Zhang Independent Director
Hai Ling Hu Independent Director
De Po Yang Independent Director